Gd2.zip

Because it is "visible" on the outside of tumor cells, several immunotherapies have been developed to target GD2:

Chimeric or humanized antibodies like Dinutuximab and Naxitamab are FDA-approved for high-risk neuroblastoma. They work by triggering immune-mediated cell death (ADCC and CDC). gd2.zip

It is synthesized in the Golgi apparatus from precursors like GM3 and GD3. Key enzymes in this pathway include ST8SIA1 (GD3 synthase) and B4GALNT1 (GD2 synthase). Because it is "visible" on the outside of

Vaccines aim to stimulate the patient's own immune system to produce anti-GD2 antibodies, while small DNA/RNA molecules (aptamers) are being researched to deliver drugs directly to GD2-positive cells. Diagnostic Significance Key enzymes in this pathway include ST8SIA1 (GD3

Present in over 98% of cases; it is a standard diagnostic and therapeutic target.

GD2 is a , a type of glycosphingolipid found on the surface of cells. It is primarily recognized as a tumor-associated antigen (TAA) because it is highly overexpressed in various cancers—specifically those of neuroectodermal origin—while remaining largely absent in most healthy adult tissues. Biological Structure and Synthesis